Quick Answer
Karyopharm Therapeutics Inc. reported R&D Expense of $125.62 million for fiscal year 2025.
Karyopharm Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $125.62M | -12.3% |
| 2024 | $143.23M | +3.2% |
| 2023 | $138.75M | -6.7% |
| 2022 | $148.66M | -7.6% |
| 2021 | $160.84M | +6.6% |
| 2020 | $150.81M | +23.3% |
| 2019 | $122.34M | -24.2% |
| 2018 | $161.37M | +50.4% |
| 2017 | $107.27M | +23.4% |
| 2016 | $86.94M | -11.1% |
| 2015 | $97.74M | +62.6% |
| 2014 | $60.13M | +111.3% |
| 2013 | $28.45M | +101.9% |
| 2012 | $14.10M | +63.5% |
| 2011 | $8.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.54M | -15.5% | -6.8% |
| June 30, 2025 | $32.79M | -14.6% | -5.3% |
| March 31, 2025 | $34.62M | -2.3% | -4.2% |
| September 30, 2024 | $36.13M | +1.6% | -5.8% |
| June 30, 2024 | $38.37M | +21.9% | +8.3% |
| March 31, 2024 | $35.42M | +9.5% | -0.4% |
| September 30, 2023 | $35.55M | +13.4% | +12.9% |
| June 30, 2023 | $31.48M | -29.0% | -2.7% |
- Karyopharm Therapeutics Inc. showed a decrease of -12.3% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Karyopharm Therapeutics Inc.’s r&d expense has grown by 1356.8% (from $8.62 million to $125.62 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: